Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Stopping Pain in Its Tracks: Optimizing Acute Migraine Therapy

Premiere Date: Wednesday, December 8, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, December 14, 2022
Note: Credit Is No Longer Available

Faculty

Jessica Ailani, MD, FAHS, FAAN (Moderator) Director, Georgetown Headache Center Vice Co-Chair, Strategic Planning Neurology Professor of Clinical Neurology MedStar Georgetown University Hospital Washington, DC

Peter J. Goadsby, MD, PhD  Professor of Neurology University of California, Los Angeles Los Angeles, CA King's College London, England

Gretchen E. Tietjen, MD  Distinguished University Professor Emerita of Neurology University of Toledo College of Medicine and Life Sciences Toledo, OH

Statement of Need

Migraine affects approximately 18% of women and 6% of men in the United States and has consistently been the fourth or fifth most common reason for emergency department (ED) visits. Almost 75% of people with migraine report reduced ability to function during episodes, creating a substantial burden that chronically and significantly impacts quality of life (QoL). Optimal management for acute migraine requires health care professionals (HCPs) to educate patients on their condition and treatment options, and to develop individualized treatment plans. No single treatment is ideal for all patients, and comorbidities or concomitant medications can cause inadequate efficacy, intolerable side effects, or simply limit treatment options. However, recently approved therapies with novel migraine-specific mechanisms of action (MOAs) offer an important expansion for HCPs to utilize in migraine management.

In this CME Outfitters Live and OnDemand program, expert faculty will discuss strategies for addressing the challenges in the management of acute migraine, efficacy and safety data of recently approved therapies, and how best to implement patient-centered approaches to individualize treatment strategies for patients with migraine.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Develop strategies to address the challenges in acute management of migraine.
• Apply data on efficacy and safety of recently approved therapies for acute treatment of migraine to treatment decisions for patients with migraine.
• Implement patient-centered approaches to individualize treatment strategies for patients with migraine.

Financial Support

Supported by an educational grant from AbbVie Inc. and Biohaven Pharmaceuticals.

Target Audience

Neurologists, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Ailiani reports she a consultant for AbbVie Inc.; Amgen Inc.; Axsome Therapeutics, Inc.; BioDelivery Sciences International, Inc.; Biohaven Pharmaceuticals; Eli Lilly and Company; GlaxoSmithKline; Impel NeuroPharma, Inc.; Lundbeck; Neso; Neurolief Inc.; Satsuma Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; and Theranica Bio-Electronics. Clinical trial grants are paid to her institution from Allergan; American Migraine Foundation; Biohaven Pharmaceuticals; Eli Lilly and Company; Satsuma Pharmaceuticals, Inc.; and Zosano Pharma Corporation. She serves on the speakers bureau for Allergan/AbbVie Inc.; Amgen Inc.; Biohaven Pharmaceuticals; Eli Lilly and Company; Lundbeck; and Teva Pharmaceuticals USA, Inc. She is ownership of stocks for Ctrl M Health, She provides editorial services for Current Pain and Headache Reports; Section editor, Unusual Headache Syndromes; NeurologyLive; SELF (Medical reviewer).

Dr. Goadsby reports he receives research grants from Amgen Inc.; Celgene Corporation; and Eli Lilly and Company. He is a consultant for AEON Biopharma; Allergan/AbbVie Inc.; Amgen Inc.; Biohaven Pharmaceuticals; Dr. Reddy's Laboratories Ltd.; Eli Lilly and Company; Epalex Corp.; GlaxoSmithKline; Impel NeuroPharma, Inc.; Lundbeck; Novartis; Pfizer Inc.; Praxis Precision Medicines; Sanofi; Santara Therapeutics; Satsuma Pharmaceuticals, Inc.; Teva Pharmaceuticals; and Trigemina, Inc. He has a patent for magnetic stimulation for headache (licensed to eNeura, no fees, No. WO2016090333 A1).

Dr. Tietjen reports that she is on the medical advisory panel for Lundbeck.

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.

Jeffrey Helfand DO (peer reviewer) has no disclosures to report.

Noreen Iftikhar, MD (planning committee) has no disclosures to report.

Janan Sewar, PharmD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).